UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

 
SCHEDULE 13G
 
Under the Securities Exchange Act of 1934
 



ZYMOGENETICS, INC.
(Name of Issuer)
 
Common Stock
(Title of Class of Securities)
 
98985T 10 9
(CUSIP Number)
 
December 31, 2002
(Date of Event which Requires Filing of this Statement)

 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
o Rule 13d-1(b)
 
o   Rule 13d-1(c)
 
x   Rule 13d-1(d)
 
 
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
 
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
Page 1 of 5
 
 
CUSIP No. 98985T 10 9
13G
 
1.
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
NOVO NORDISK A/S
 
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) o
   
(b) o
3.
SEC USE ONLY
   
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
Denmark
 
 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
SOLE VOTING POWER 22,143,320
   
6.
SHARED VOTING POWER 0
   
7.
SOLE DISPOSITIVE POWER 22,143,320
   
   
8.
SHARED DISPOSITIVE POWER 0
   
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
22,143,320
 
  
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS)
Not applicable
  
 o
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
26.7%
 
  
12.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
Not applicable
 
  
 
Page 2 of 5
 

Item 1(a).
Name of Issuer:
 
ZYMOGENETICS, INC.
 
Item 1(b).
Address of Issuer’s Principal Executive Offices:
 
1201 Eastlake Avenue East, Seattle, WA 98102
 
Item 2(a).
Name of Person(s) Filing:
 
NOVO NORDISK A/S
 
Item 2(b).
Address of Principal Business Office or, if None, Residence:
 
Novo Allé 1, DK-2880 Bagsværd, Denmark
 
Item 2(c).
Citizenship:
 
Not applicable
 
Item 2(d).
Title of Class of Securities:
 
Common stock
 
Item 2(e).
CUSIP Number:
 
98985T 10 9
 
Item 3.
If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
 
 
Not applicable
 
Item 4.
Ownership.
 
Provide the following information regarding the aggregate number and percentage of the class of securities of issuer identified in Item 1.
 
 
(a)
Amount beneficially owned:  22,143,320
 
 
(b)
Percent of class:  26.7%
 
 
(c)
Number of shares as to which such person has:
 
 
(i)Sole power to vote or to direct the vote:  22,143,320
 
 
(ii)Shared power to vote or to direct the vote:  0
 
 
(iii)Sole power to dispose or to direct the disposition of:  22,143,320
 
 
(iv)Shared power to dispose or to direct the disposition of:  0
 
Item 5.
Ownership of Five Percent or Less of a Class.
 
Not applicable
 
Item 6.
Ownership of More than Five Percent on Behalf of Another Person.
 
Not applicable
 
Page 3 of 5
 
 
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
 
Novo Nordisk A/S directly holds 22,143,320 shares of common stock in ZYMOGENETICS, INC. In addition, Novo A/S, the parent holding company of Novo Nordisk A/S, directly holds 866,541 shares of common stock in ZYMOGENETICS, INC.
 
Item 8.
Identification and Classification of Members of the Group.
 
Not applicable
 
Item 9.
Notice of Dissolution of Group.
 
Not applicable
 
Item 10.
Certifications.
 
Not applicable
 
Page 4 of 5
 
 
SIGNATURE
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
 January 8, 2010
(Date)
 
/s/ Jesper Brandgaard
(Signature)
 
Jesper Brandgaard / Chief Financial Officer
(Name/Title)


The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative.  If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference.  The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
 
Attention.  Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001)
 

Page 5 of 5